Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813845 | 0.83 | TSHR (0.33) | KDM4E | |
| SCHEMBL314763 | 0.82 | TSHR (0.40) | SMN1; SMN2 | |
| SCHEMBL1143957 | 0.80 | SMN1; SMN2 (0.38) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL6132567 | 0.80 | KCNA3 (0.35) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2499529 | 0.80 | LTA4H (0.34) | ALDH1A1 | |
| SCHEMBL6132896 | 0.79 | KDM4E (0.35) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL49802 | 0.78 | — | — | |
| SCHEMBL6238419 | 0.78 | JAK2 (0.33) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL6538591 | 0.78 | KCNA3 (0.41) | ALDH1A1 | |
| SCHEMBL7779040 | 0.77 | L3MBTL1 (0.37) | KDM4EALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107721836-A | One kind synthesis 1,7 2（4 hydroxy phenyls）The method of the ketone of 1,4 diene of heptane 3 | 沈阳药科大学 | 2018-02-23 | — | — | CN | claimed |
| CN-100402152-C | Trimerisation of olefins using a catalyst comprising a source of chromium, molybdenum or tungsten and a ligand comprising at least one phosphorus, arsenic or antimony atom bound to at least one (hetero) hydrocarbyl group | BP CHEM INT LTD (GB) | 2008-07-16 | — | — | CN | claimed |
| CN-1630554-A | Trimerisation of olefins using a catalyst containing chromium, molybdenum or tungsten and a ligand containing phosphorus, arsenic or antimony | BP CHEM INT LTD (GB) | 2005-06-22 | — | — | CN | claimed |
| US-20050020788-A1 | Olefin trimerisation using a catalyst comprising a source of chromium, molybdenum or tungsten and a ligand containing at least one phosphorous, arsenic or antimony atom bound to at least one (hetero) hydrocarbyl group | BP CHEMICALS LIMITED | 2005-01-27 | — | — | US | claimed |
| US-6800702-B2 | CONTACTING A MONOMERIC OLEFIN OR MIXTURE OF OLEFINS UNDER TRIMERISATION CONDITIONS WITH A CATALYST WHICH COMPRISES (A) A SOURCE OF CHROMIUM, MOLYBDENUM OR TUNGSTEN (B) A LIGAND CONTAINING AT LEAST ONE PHOSPHORUS, ARSENIC OR ANTIMONY ATOM | BP CHEMICALS LIMITED (GB) | 2004-10-05 | — | — | US | claimed |
| US-20030166456-A1 | Olefin trimerisation using a catalyst comprising a source of chromium,molybdenum or tungsten and a ligand containing at least one phosphorous, arsenic or antimony atom bound to at least one (hetero)hydrocarbyl group | BARCLAYS BANK PLC (GB) | 2003-09-04 | — | — | US | claimed |
| EP-1299189-A1 | OLEFIN TRIMERISATION USING A CATALYST COMPRISING A SOURCE OF CHROMIUM, MOLYBDENUM OR TUNGSTEN AND A LIGAND CONTAINING AT LEAST ONE PHOSPHOROUS, ARSENIC OR ANTIMONY ATOM BOUND TO AT LEAST (HETERO)HYDROCARBYL GROUP | BP Chemicals Limited (GB) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004119-A1 | OLEFIN TRIMERISATION USING A CATALYST COMPRISING A SOURCE OF CHROMIUM, MOLYBDENUM OR TUNGSTEN AND A LIGAND CONTAINING AT LEAST ONE PHOSPHOROUS, ARSENIC OR ANTIMONY ATOM BOUND TO AT LEAST ONE (HETERO)HYDROCARBYL GROUP | BP CHEMICALS LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| WO-2024037527-A1 | BTK DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024032704-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023242597-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| CN-113302172-B | Enantioselective preparation of chiral tetraarylmethanes | 香港科技大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-113831296-B | 1-phenyl-3- (4- (pyrimidine-5-ylamino) phenyl) prop-2-en-1-one compounds and uses thereof | 北京理工大学 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-5137889-A | Hypotensive agents; coronary vasodilators; calcium antagonists; antiinflammatory agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-11 | — | — | US | disclosed |
| US-5034395-A | Hypotensive agents, carboxylated dihydropyridines | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0403026-A1 | 12-Substituted-12H-dibenzo(D,G)(1,3)dioxocin-6-carboxylic acids, herbicidal compositions, and a method of controlling undesirable vegetation | DowElanco (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4795814-A | CORONARY VASODILATORS, HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTTS, ENZYME INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-03 | — | — | US | disclosed |
| EP-0173126-A1 | Process for preparing novel dihydropyridine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166456-A1 | Olefin trimerisation using a catalyst comprising a source of chromium,molybdenum or tungsten and a ligand containing at least one phosphorous, arsenic or antimony atom bound to at least one (hetero)hydrocarbyl group | OSBP, OSBPL8, OSBP2 | PTPN1 1114/4885KDM4E 4620/4885ALDH1A1 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.